5441722025-10-012025-12-315441722025-12-315441722025-04-012025-12-315441722025-10-012025-12-31in-capmkt:OtherExpenses1Member5441722025-04-012025-12-31in-capmkt:OtherExpenses1Member5441722025-10-012025-12-31in-capmkt:ReportableSegments1Member5441722025-10-012025-12-31in-capmkt:ReportableSegments2Member5441722025-10-012025-12-31in-capmkt:ReportableSegments3Member5441722025-04-012025-12-31in-capmkt:ReportableSegments1Member5441722025-04-012025-12-31in-capmkt:ReportableSegments2Member5441722025-04-012025-12-31in-capmkt:ReportableSegments3Member5441722025-10-012025-12-31in-capmkt:ReportableSegments1Member5441722025-10-012025-12-31in-capmkt:ReportableSegments2Member5441722025-10-012025-12-31in-capmkt:ReportableSegments3Member5441722025-04-012025-12-31in-capmkt:ReportableSegments1Member5441722025-04-012025-12-31in-capmkt:ReportableSegments2Member5441722025-04-012025-12-31in-capmkt:ReportableSegments3Member5441722025-10-012025-12-31in-capmkt:ReportableSegments1Member5441722025-12-31in-capmkt:ReportableSegments1Member5441722025-10-012025-12-31in-capmkt:ReportableSegments2Member5441722025-12-31in-capmkt:ReportableSegments2Member5441722025-10-012025-12-31in-capmkt:ReportableSegments3Member5441722025-12-31in-capmkt:ReportableSegments3Member5441722025-10-012025-12-31in-capmkt:ReportableSegments1Member5441722025-12-31in-capmkt:ReportableSegments1Member5441722025-10-012025-12-31in-capmkt:ReportableSegments2Member5441722025-12-31in-capmkt:ReportableSegments2Member5441722025-10-012025-12-31in-capmkt:ReportableSegments3Member5441722025-12-31in-capmkt:ReportableSegments3Member5441722025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15441722025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15441722025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15441722025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15441722025-10-012025-12-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares544172INDGNNOTLISTEDINE065X01017Indegene LimitedMain BoardEquity2025-04-012026-03-312026-01-292026-01-22INRMillionsQuarterlyThird quarterMulti segment2026-01-2917:30:002026-01-2918:07:00Declaration of unmodified opinion2025-10-012025-12-31UnauditedConsolidated9421000000194000000961500000000056800000004600000039600000021460000008268000000134700000001347000000874000000-55600000031800000001029000000000010290000001930000001222000000102900000001222000000048000000024.294.26004.294.26Earnings per share is not annualised for quarter and nine months ended. <BR> <BR> Notes to the Statement of Consolidated Financial Results for the quarter and nine months ended 31 December 2025 <BR> <BR> All amounts in INR millions except share data and where otherwise stated <BR> <BR> 1 The above Consolidated Financial Results of Indegene Limited the Company or the Parent or the Holding Company together with its affiliates collectively the Group have been prepared in accordance with Indian Accounting Standards Ind AS 34 Interim Financial Reporting recognition and measurement principles of Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act 2013 as amended read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 the Regulations Due to rounding off the numbers presented throughout may not add up precisely to the totals Caret Symbol in the financial information denote amounts less than INR 5 Lakh <BR> <BR> 2 The above Consolidated Financial Results have been reviewed by the Audit Committee in the meeting held on 28 January 2026 and approved by the Board of Directors at its meeting held on 29 January 2026 The statutory auditors have performed a limited review of the Consolidated Financial Results for the quarter and nine months ended 31 December 2025 and have issued an unmodified review report on the same <BR> <BR> 3 The Consolidated Financial Results for the quarter and nine months ended 31 December 2025 are available on the National Stock Exchange of India Limited URL www nseindia com the BSE Limited website URL www bseindia com and on the Companys website URL www indegene com investor relations <BR> <BR> <BR> 4 Acquisition of Biopharm Holdings Inc <BR> As on 30 September 2025 the Group has entered into a stock purchase agreement with BioPharm Parent Holding Inc BioPharm and Engage Acquisition Corp Seller to acquire 100 percent interest in BioPharm a specialized marketing services agency part of Omnicom Health Group for an aggregate purchase consideration of INR 9146 USD 104 million including deferred and contingent earn out consideration The Group believes that the acquisition will strengthen the Group s commercialization portfolio by integrating advanced AI and digital advertising technologies enabling pharmaceutical companies to achieve more precise scalable and measurable marketing outcomes Further on 01 October 2025 the Group had obtained control of BioPharm and has carried out the provisional purchase price allocation for the BioPharm acquisition during the quarter ended 31 December 2025 and the same will be finalised within the measurement period but in no event later than one year following the date of acquisition 01 October 2025 2025-04-012025-12-31UnauditedConsolidated2507100000061200000025683000000000156530000001210000008460000004864000000214840000004199000000041990000001537000000-552000000985000000032140000000000321400000084400000040580000003214000000040580000000480000000213.413.320013.413.32Other expenses2146000000Other expenses4864000000Enterprise Medical Solutions2387000000Enterprise Commercial Solutions6689000000Others345000000Enterprise Medical Solutions6761000000Enterprise Commercial Solutions17412000000Others89800000094210000002507100000000942100000025071000000Enterprise Medical Solutions612000000Enterprise Commercial Solutions1199000000Others-55000000Enterprise Medical Solutions1763000000Enterprise Commercial Solutions3280000000Others-164000000175600000048790000004600000012100000036300000055900000013470000004199000000Enterprise Medical Solutions0Enterprise Commercial Solutions0Others0000Enterprise Medical Solutions0Enterprise Commercial Solutions0Others00005 Acquisition of Warn and Co Limited <BR> On 16 October 2025 the Group acquired 100 percent interest in Warn and Co Limited a specialized transformation consulting firm for an aggregate purchase consideration of INR 464 GBP 3910k <BR> including an earnout component The acquisition has been accounted for as a business combination under Ind AS 103 The Group has carried out the provisional purchase price allocation for the Warn and Co acquisition during the quarter ended 31 December 2025 and the same will be finalised within the measurement period but in no event later than one year following the date of acquisition 16 October 2025 <BR> <BR> 6 During the year 2020 21 the Group was named in a class action lawsuit filed in the U.S. District Court of New Jersey alleging non-compliance with the Telephone Consumer Protection Act of 1991 TCPA by sending unsolicited fax advertisements without the recipients prior express invitation or permission <BR> <BR> In July 2025 the Court allowed the case to proceed as a class action. The Groups request to challenge this decision was not accepted. The matter remains ongoing and is progressing toward trial or potential settlement Mediation discussions are expected in early 2026 with the Group participating on a no admission of liability basis <BR> <BR> As of 31 December 2025 no settlement terms have been proposed or agreed and the scope of potential claimants remains uncertain. Any financial obligation would depend on valid claims being filed and cannot be reliably estimated. Accordingly no provision is considered necessary in the consolidated financial results at this stage <BR> <BR> 7 On 10 November 2025 Indegene Ireland Limited Company s wholly owned subsidiary has signed a Share Purchase Agreement SPA to acquire 100 percent equity shares in CAKE Kommunikations Holding GmbH an SPV created to hold 70 percent in Cake Kommunikations GmbH AT 100 percent in CAKE Kommunikations GmbH DE and 100 percent in CAKE Kommunikations AG Switzerland and 30 in Cake Kommunikations GmbH AT from from Werner Hinterberger Collectively Cake Group for an amount not exceeding EUR 8500k including earnout liability subject to net working capital or net debt adjustments <BR> <BR> The acquisition is subject to meeting the closing conditions as defined in the SPA which are yet to be completed as on 31 December 2025 <BR> <BR> 8 On 31 December 2025 Indegene Inc and Trilogy Writing and Consulting GmbH the step-down subsidiaries of the Company signed a Share Purchase Agreement to acquire 100 Percentage equity shares of Trilogy Writing & Consulting Inc formerly Trilogy Writing and Consulting ULC a wholly owned subsidiary of Trilogy Writing and Consulting GmbH for a cash consideration of EURO 329014 Subsequently on 01 January 2026 the Companys step down subsidiaries Indegene Aptilon Services Inc and Trilogy Writing and Consulting Inc both wholly owned by Indegene Inc USA amalgamated to form Indegene Healthcare Canada Inc <BR> <BR> 09 On 21 November 2025 the Government of India notified provisions of the Code on Wages 2019 the Industrial Relations Code 2020 the Code on Social Security 2020 and the Occupational Safety Health and Working Conditions Code 2020 Labour Codes which consolidate twenty nine existing labour laws into a unified framework governing employee benefits during employment and post-employment The Labour Codes amongst other things introduces changes including a uniform definition of wages and enhanced benefits relating to leave The Group based on the evaluation of the existing wage structure has concluded that these changes do not have any material impact on the Group s financial results In case of any further clarification from the Government on other aspects of the New Labour Codes the Group will evaluate and account for differential impact if any in subsequent periods on the consolidated financial results <BR> <BR> 10 Segment information <BR> Effective 01 October 2025 the Group has reorganised its segments by merging Brand Activation Segment as part of Enterprise Commercial Solutions in line with the manner in which the Chief operating decision maker reviews and evaluates performance of the business of the Group Pursuant to the above in accordance with the requirement specified in Ind AS 108 the comparative period information has been recasted to give the effect of this change <BR> <BR> Subsequent to the above change the Group will now have only 2 reportable segment ie Enterprise Commercial Solutions and Enterprise Medical Solutions <BR> <BR> Others mainly comprises of consultancy and clinical business <BR> <BR> Notes on Segment information <BR> Operating segments are identified as components of an enterprise for which discrete financials information is available that is evaluated regularly by the chief operating decision maker In deciding how to allocate resources and assessing performance the Groups chief operating decision maker is the Chief Executive Officer and Executive Director <BR> <BR> Assets and liabilities used in the Groups business are not identified to any of the operating segments as these are used interchangeably between segments. Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous <BR> <BR> Other unallocable expenditure net of unallocable income for the three months ended 31 Dec 2025 includes depreciation and amortisation expense INR 396 and unallocable expenses INR 161 net of other income INR 194 <BR> <BR> Other unallocable expenditure net of unallocable income for the nine months ended 31 Dec 2025 includes depreciation and amortisation expense INR 846 and unallocable expenses INR 325 net of other income INR 612 Remeasurement of defined benefit obligation60000006000000Remeasurement of defined benefit obligation4200000042000000200000011000000Exchange differences on translating the financial statements of foreign operations189000000189000000Exchange differences on translating the financial statements of foreign operations81300000081300000000193000000844000000UnauditedtrueDeloitte Haskins & Sellstrue2028-04-30